Author
Biblio print
Tree Display
AceDB Schema
XML Display
Feedback

Author Report for: Potter PM

Name Class
Potter PMFull_namePotter Philip M
First_namePhilip PM
AddressMailSt. Jude Children's Research Hospital; Chemical Biology and Therapeutics; 262 Danny Thomas Place; Memphis; 38112
CountryUSA
E_mailphil.potter@stjude.org
Phone+19015952825
PaperYoon_2006_Mol.Cancer.Ther_5_1577
Bencharit_2003_Nat.Struct.Biol_10_349
Bencharit_2002_Nat.Struct.Biol_9_337
Danks_1998_Cancer.Res_58_20
Wierdl_2000_Biochem.Pharmacol_59_773
Hatfield_2010_Br.J.Pharmacol_160_1916
Stoddard_2010_J.Pestic.Sci_35_240
Guichard_1998_Clin.Cancer.Res_4_3089
Potter_1998_Cancer.Res_58_3627
Potter_1998_Cancer.Res_58_2646
Tsurkan_2013_Chem.Biol.Interact_203_226
Hatfield_2013_J.Nat.Prod_76_36
Cushman_2013_J.Biol.Chem_288_19177
Metz_2013_Stem.Cells.Transl.Med_2_983
Bencharit_2003_Chem.Biol_10_341
Wadkins_2004_Mol.Pharmacol_65_1336
Harel_2005_Mol.Pharmacol_67_1874
Hatfield_2016_Chem.Biol.Interact_259_327
Argikar_2016_AAPS.J_18_1391
Wierdl_2016_Br.J.Pharmacol_173_2811
Gutova_2017_Mol.Ther.Oncolytics_4_67
Hatfield_2017_J.Med.Chem_60_1568
Fleming_2007_Biochemistry_46_5063
Hemmert_2011_PLoS.One_6_e17441
Hemmert_2010_Mol.Pharmacol_77_508
Wadkins_2005_J.Med.Chem_48_2906
Fleming_2005_J.Mol.Biol_352_165
Harel_2005_Chem.Biol.Interact_157-158_153
Hyatt_2005_Chem.Biol.Interact_157-158_247
Tyminski_2005_Cancer.Res_65_6850
Bencharit_2006_J.Mol.Biol_363_201
Hyatt_2006_Mol.Cancer.Ther_5_2281
Godin_2006_Drug.Metab.Dispos_34_1764
Hyatt_2007_J.Med.Chem_50_5727
Barthel_2008_J.Med.Chem_51_298
Streit_2008_Biol.Chem_389_149
Hatfield_2008_Expert.Opin.Drug.Metab.Toxicol_4_1153
Crow_2008_Biochim.Biophys.Acta_1781_643
Harada_2009_Bioorg.Med.Chem_17_149
Wierdl_2008_Cancer.Gene.Ther_15_183
Crow_2010_Biochim.Biophys.Acta_1801_31
Hicks_2009_J.Med.Chem_52_3742
Crow_2007_Toxicol.Appl.Pharmacol_221_1
Danks_2007_Cancer.Res_67_22
Wadkins_2007_Mol.Pharmacol_71_713
Gutova_2010_Curr.Stem.Cell.Res.Ther_5_273
Holmes_2010_Mamm.Genome_21_427
Connelly_2011_Biochim.Biophys.Acta_1811_39
Hatfield_2011_Biochem.Pharmacol_81_24
Young_2010_J.Med.Chem_53_8709
Crow_2012_Toxicol.Appl.Pharmacol_258_145
Edwards_2011_Biotechnol.Prog_27_863
Hatfield_2011_Expert.Opin.Ther.Pat_21_1159
Parkinson_2011_Bioorg.Med.Chem_19_4635
Xie_2010_Chem.Res.Toxicol_23_1890
Aboody_2006_PLoS.One_1_e23
Crow_2012_Biochem.Pharmacol_84_1215
Danks_1999_Clin.Cancer.Res_5_917
Danks_2004_Methods.Mol.Med_90_247
Hicks_2007_Bioorg.Med.Chem_15_3801
Hyatt_2007_J.Med.Chem_50_1876
Hyatt_2005_J.Med.Chem_48_5543
Iyengar_2001_Cancer.Res_61_3045
Khanna_2000_Cancer.Res_60_4725
Lu_2009_AAPS.J_11_120
Meck_2001_Cancer.Res_61_5083
Moore_1984_Carcinogenesis_5_949
Morton_2005_Cancer.Chemother.Pharmacol_56_629
Morton_2000_Mol.Biotechnol_16_193
Morton_1999_Cancer.Res_59_1458
Morton_2000_Cancer.Res_60_4206
Pawlik_2000_Mol.Ther_1_457
Potter_2000_Mol.Biotechnol_15_105
Potter_2006_Curr.Med.Chem_13_1045
Potter_1998_Cytometry_32_223
Redinbo_2003_Biochem.Soc.Trans_31_620
Redinbo_2005_Drug.Discov.Today_10_313
Ross_2006_Biochem.Pharmacol_71_657
Stubdal_2003_Cancer.Res_63_6900
Wadkins_2001_Mol.Pharmacol_60_355
Wadkins_1999_Cancer.Res_59_3424
Wagner_2002_Cancer.Res_62_5001
Wierdl_2003_J.Pharmacol.Exp.Ther_304_699
Wierdl_2004_Biochemistry_43_1874
Wierdl_2001_Cancer.Res_61_5078
Wierdl_2005_Curr.Hematol.Rep_4_294
Wierdl_2003_Mol.Pharmacol_64_279
Yoon_2004_Mol.Cancer.Ther_3_903
Yoon_2003_Mol.Cancer.Ther_2_1171
Yoon_2003_Bioorg.Med.Chem_11_3237
Yoon_2005_Curr.Med.Chem.Anticancer.Agents_5_107
Yu_2012_J.Mol.Model_18_2869
Binder_2018_Eur.J.Med.Chem_149_79
Hatfield_2018_J.Nat.Prod_81_2410
Laizure_2020_Xenobiotica_50_245
Send your questions or comments to :
Mail to: Nicolas Lenfant, Thierry Hotelier, Yves Bourne, Pascale Marchot and Arnaud Chatonnet.
Please cite: Lenfant 2013 Nucleic.Acids.Res. or Marchot Chatonnet 2012 Prot.Pept Lett.
For technical information about these pages see:
ESTHER Home Page and ACEDB Home Page
AcePerl Lincoln Stein Home Page
webmaster

Acknowledgements and disclaimer